The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with
hypertrophic cardiomyopathy (HCM) at high risk of sudden cardiac death. The heterogeneity …

Background Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined
by left ventricular hypertrophy that cannot be explained by another cardiac or systemic …

Background Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in
patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral …

Purpose The present study evaluated how heart failure (HF) negatively impacts health-
related quality of life (HRQoL) in hypertrophic cardiomyopathy (HCM) patients and explored …

Background Although highly effective in preventing arrhythmic death, there is a high
prevalence of anxiety, depression and reduced quality of life among patients who have …

Aims To assess the effects of mavacamten on health-related quality-of-life (HRQoL) in
symptomatic obstructive hypertrophic cardiomyopathy (HCM) and estimate health utilities by …

Aims To conduct a contemporary cost-effectiveness analysis examining the use of
implantable cardioverter defibrillators (ICDs) for primary prevention in patients with …

Introduction There is limited evidence on therapies for obstructive hypertrophic
cardiomyopathy (HCM), and data regarding treatment patterns and cost are scarce. This …

Although limb–girdle muscular dystrophies (LGMD) can cause permanent disability, to date
there are no studies that examined quality of life (QoL) in these patients. Our aim was to …

Heart failure affects nearly 26 million people worldwide. Patients with heart failure are
frequently affected with atrial fibrillation, and the interrelation between these pathologies is …